mmp300  (R&D Systems)

Journal: Rheumatology (Oxford, England)

Article Title: EPCR deficiency ameliorates inflammatory arthritis in mice by suppressing the activation and migration of T cells and dendritic cells

doi: 10.1093/rheumatology/kead230

Figure Lengend Snippet: Plasma cytokines and anti-CII antibodies and tissue Th1/2/Th17/Treg cells in mice with CIA. (A) IL-17, IFN-γ, MMP-3, TGF-1β and anti-CII antibodies IgG1, IgG2a and IgG2b in plasma from EPCR KO and WT mice with CIA at day 28 after arthritis induction, measured by ELISA ( n = 20). (B) Gate strategies for Th and Treg cell detection by flow cytometry. (C) Th1, Th2, Th17 and Treg cells and (D) chemokine receptors CXCR3 (CD183), CXCR5 (CD185), CCR6 (CD196) and CCR7 (CD197) on CD3 + CD4 + T cells from blood, spleen, lymph node (LN) and synovium of WT and EPCR KO mice at day 28 after arthritis induction, detected by flow cytometry ( n = 6). Data are shown as mean ( s . d .). * P < 0.05, ** P < 0.01 vs WT

Article Snippet: Mouse anti-CII antibodies (IgG1, IgG2a and IgG2b; Thermo Fisher Scientific Australia), mouse cytokines TGF-β1, IL-4, IL-17, IFN-γ and TNF-α and MMP-3 were measured using ELISA kits (R&D Systems) according to the manufacturer’s instructions.

Techniques: Clinical Proteomics, Enzyme-linked Immunosorbent Assay, Flow Cytometry

Journal: Rheumatology (Oxford, England)

Article Title: EPCR deficiency ameliorates inflammatory arthritis in mice by suppressing the activation and migration of T cells and dendritic cells

doi: 10.1093/rheumatology/kead230

Figure Lengend Snippet: The effect of EPCR on immune cells from WT or EPCR KO mice with CIA and the effect of blocking EPCR on PBMCs from patients with RA. (A-C) The levels of immune cells including CD3, CD4 and CD8 T cells, NK cells, NK T cells (NK/T), monocytes (Mono), myeloid-derived suppressor cells (MDSCs) and B cells within blood, lymph node (LN), spleen and synovium (Syn) from WT or EPCR KO mice ( n = 5 mice) with CIA, detected by flow cytometry. (D) EPCR expression on CD3 and CD4 T cells within PBMCs from patients with RA or matched HCs ( n = 6). (E) The percentages of Th1, Th2, Th17 and Treg cells in CD3 + CD4 + T cells within RA PBMCs treated with human EPCR blocking antibody RCR252 (R252), non-blocking antibody RCR92 (R92), TNF inhibitor ADA and ETA (all 10 µg/ml) for 24 h, detected by flow cytometry ( n = 4). (F) MMP-2 and MMP-9 and IFN-γ in culture supernatants of RA PBMCs after 24 h treatment ( n = 4). MMP-2 and MMP-9 were detected by zymography and IFN-γ by ELISA. Data are shown as mean ( s . d .). ST: MMP-2 and MMP-9 standard; Con: control. * P < 0.05, ** P < 0.01, *** P < 0.001 vs WT, HCs or Con

Article Snippet: Mouse anti-CII antibodies (IgG1, IgG2a and IgG2b; Thermo Fisher Scientific Australia), mouse cytokines TGF-β1, IL-4, IL-17, IFN-γ and TNF-α and MMP-3 were measured using ELISA kits (R&D Systems) according to the manufacturer’s instructions.

Techniques: Blocking Assay, Derivative Assay, Flow Cytometry, Expressing, Zymography, Enzyme-linked Immunosorbent Assay, Control